SGMO Sangamo BioSciences: רווח נקי למניה אחת בשנים עשר החודשים האחרונים

The confirmed price history on the EPS (TTM) chart for Sangamo Therapeutics (SGMO) is 14.10. Sangamo Therapeutics is recognized as a leading innovator in gene editing, which provides the company with significant industry credibility. The business relies on partnerships with tech giants, monetizing its DNA IT developments through licensing. Treatment reliability is guaranteed by a strict temperature regime during the transportation of biomaterials.
Sangamo Therapeutics Inc. - פילוחים אנליטיים ומדדי מפתח (SGMO)

Year-over-year (YoY) EPS growth (TTM) measures the dynamics of net profit per share over a rolling twelve-month period. By analyzing the current EPS YoY TTM growth rate, an investor can identify real acceleration in profitability while excluding one-time factors. This metric is calculated as the percentage change in earnings over a year, stripping seasonality from the result. For Sangamo Therapeutics (SGMO), this indicator is critical, as it reflects the efficiency of capital burn against the backdrop of gene editing risks.